Curriculum Vitae Daniela Laimer-Gruber

Name: Daniela Laimer-Gruber, PhD

Education&Career

2016-present: Postdoc-postion at the PIL (Preaclinical Imaging Lab; head: Prof. Thomas Helbich)

2014-2016: maternity leave.

2010 to end of 2013: employment as scientist/Postdoc at the Department of Dermatology, Medical University of Vienna (Prof. Tamara Kopp, Dr. Christine Bangert).

Doctoral Thesis: "PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas". Development of a new and highly effective therapy for ALCL (Anaplastic Large Cell Lymphoma). Published as: Laimer, D. et.al., Nature Medicine, 2012. 18(11):1699-704. PhD-course (molecular signal transduction) at the laboratory of Prof. Lukas Kenner, Institute of Clinical Pathology, Medical University Vienna, Austria. Official completion of the PhD-course with the title Doctor of Philosophy at 12/9/2013. Grade received: 1, graduated with distinction.

Diploma thesis: „Effects of progesterone and estrogen on proliferation and maturation of human erythroid cells", experiments carried out at the medical university of Vienna, University Clinic of Gynaecology, Clinical Department for Gynaecological Endocrinology and Sterility Treatment. Grade received: 1

1999-2005: Biology-course, University of Vienna, department of genetics; main subject: cyto- and developmental genetics; choice subject: evolutionary biology. Official completion of the Biology-course with the title Magister Rerum Naturae at 5/12/2005.

Scientific Awards	**7**
Original Articles (Peer Reviewed Journals)	**6**
Impact Factor Total	**60,44**

Main fields of interest/expertise: Strong background in medical research, especially imaging (optical/fluorescent/luminescent imaging in live animals, tissue imaging), transgenic and xenografted mouse models, double/triple immunofluorescent stainings as well as immunohistochemistry, tumor cell/tumor stroma interactions, immunology. Also knowledgeable in cytokine and growth factor signalling as well as autoimmune skin diseases, cell culture, qPCR, PCR, ChIP, DNA-Microarrays, ELISA, Western Blot. TOEFL (Test of English as a Foreign Language): 274 of 300 possible points.

Advisory Functions

Member of the Advisory Board of the Medical University of Vienna in 2013 as a representative for the PhD-students

Awards

Novartis Price 2014

VFWF award for the best dissertation in the year 2013

Sanofi-Aventis award 2013, Medical University of Vienna, Austria

Researcher of the month, Medical University of Vienna, April 2013

YSA publication price: best publication by a PhD student in 2013, Medical University of Vienna, Austria

Best Poster
Microenvironment, Vasculature and Metastasis Symposium, Vienna, Austria, November 2012

Best oral presentation
7th PhD-Symposium, Vienna, Austria, 16-18 June 2011, Oral Session 4. Published: 2011

Abstracts

Laimer D. et.al., Evaluation of the anti-neoplastic potential of orally applied metronomic temozolomide alone and in combination with rapamycin. 9th PhD-Symposium of the MUW, Abstract P1, page 58

Laimer, D., et al., PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Microenvironment, Vasculature and Metastasis Symposium of the Medical university of Vienna, 2012.

Laimer, D., et al., PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. 7th PhD-Symposium of the Medical University of Vienna, 2011. Oral Session 4.

Hamacher, F. et al., Role of miRNAs in ALK(+) and ALK(-) anaplastic large cell lymphoma. Onkologie, 2010. 33:209-209

Hamacher, F., et al., Die Rolle von miRNAs in ALK+ und ALK- grosszelligem anaplastischen Lymphom. Jahrestagung der deutschen Gesellschaft für Hämatologie und Onkologie, 2010. Abstract: V699

Thallinger, C., et al., Loss of JunB and cJun in T-cell lymphomas results in loss of PDGFRß expression and increased survival advantage. Jahrestagung der österreichischen Gesellschaft für Dermatologie und Venerologie, 2009. Page: 34

Laimer, D., et al., Loss of JunB and cJun in NPM-ALK induced ALCL results in loss of PDGFRB expression, which leads to increased survival advantage and reduced tumor size. 5th PhD-Symposium of the Medical University of Vienna, 2009. Page: 39

Laimer, D., et al., Loss of JunB and cJun in NPM-ALK induced ALCL results in loss of PDGFRß expression and increased survival advantage. AACR Annual Meeting, 2009. Abstract No: 297

Merkel, O., et al., A role for AP1 regulated miRNAs in NPM-ALK lymphoma. AACR Annual Meeting, 2009.Abstract No: 2653

Laimer, D., et al., Loss of JunB and cJun in NPM-ALK induced ALCL results in loss of PDGFRB expression, which leads to increased survival advantage and reduced tumor size. 92. Jahrestagung der deutschen Gesellschaft für Patholgie, 2008.

Laimer, D., et al., The role of c-Jun and JunB for lymphoma development . 4th PhD-Symposium of the Medical University of Vienna, 2008. Abstract No: P92

Laimer, D., et al., Role of Junb in ALCL lymphoma development. 12th Congress of the European-Hematology-Association, 2007. Meeting Abstract: 0919. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Volume: 92 Pages: 344-344